Contineum Therapeutics, Inc. (CTNM) Stock

Contineum Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in San Diego, California, is dedicated to the discovery and development of innovative oral small molecule therapies. Focused on addressing critical unmet needs in neuroscience, inflammation, and immunology, the company leverages its expertise to advance transformative treatments.

At the forefront of Contineum Therapeutics' pipeline is PIPE-791, a groundbreaking brain-penetrant small molecule inhibitor targeting the lysophosphatidic acid 1 receptor (LPA1R). This lead asset holds promise for treating conditions such as idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS), aiming to improve patient outcomes through targeted therapeutic interventions.

In addition to PIPE-791, the company is acthively developing PIPE-307, a selective small molecule inhibitor of the muscarinic type 1 M1 receptor designed to address depression and relapse-remitting MS. Contineum Therapeutics also pursues CTX-343, a peripherally-restricted LPA1R antagonist, further expanding its portfolio of novel therapeutic candidates. Originally founded as Pipeline Therapeutics, Inc., the company rebranded as Contineum Therapeutics, Inc. in November 2023, reflecting its evolving focus and commitment to advancing innovative treatments.